cilostazol has been researched along with Coronary Thrombosis in 22 studies
Coronary Thrombosis: Coagulation of blood in any of the CORONARY VESSELS. The presence of a blood clot (THROMBUS) often leads to MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cilostazol has been reported to control restenosis after balloon angioplasty (BA)." | 6.71 | Balloon angioplasty plus cilostazol administration versus primary stenting of small coronary artery disease: final results of COMPASS. ( Awata, N; Kobayashi, T; Nasu, K; Takeda, Y; Tsuchikane, E, 2004) |
| "Cilostazol, which was administered to prevent subacute stent thrombosis after percutaneous coronary intervention, might have contributed to the transient intraventricular obstruction." | 5.34 | Dynamic intraventricular obstruction in acute myocardial infarction with administration of cilostazol. ( Hoyano, M; Maeda, C; Miida, T; Oda, H; Ozaki, K; Takahashi, K; Takayama, T; Tsuchida, K; Yanagawa, T, 2007) |
| "Cilostazol has been reported to control restenosis after balloon angioplasty (BA)." | 2.71 | Balloon angioplasty plus cilostazol administration versus primary stenting of small coronary artery disease: final results of COMPASS. ( Awata, N; Kobayashi, T; Nasu, K; Takeda, Y; Tsuchikane, E, 2004) |
| "Cilostazol is a potent antiplatelet agent with less serious side effects." | 2.69 | Comparison of cilostazol versus ticlopidine therapy after stent implantation. ( Hong, MK; Kim, HS; Kim, JJ; Lee, CW; Lee, HJ; Park, HK; Park, SJ; Park, SW, 1999) |
| " The included end-points were major adverse cardiovascular event (MACE), target lesion revascularization (TLR), target vessel revascularization (TVR), death, myocardial infarction (MI), stent thrombosis, bleeding and other drug adverse events." | 2.50 | Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons. ( Chen, Y; Huang, X; Tang, Y; Xie, Y; Zhang, Y, 2014) |
| "Cilostazol is a vasodilating antiplatelet agent that reversibly inhibits platelet aggregation induced by many factors." | 2.41 | Cilostazol for prevention of thrombosis and restenosis after intracoronary stenting. ( El-Beyrouty, C; Spinler, SA, 2001) |
| "Cilostazol has also been reported to inhibit smooth muscle cell proliferation in vitro and has been demonstrated in a clinical study to favorably alter plasma lipids: to decrease triglyceride and to increase HDL-cholesterol levels." | 2.41 | Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. ( Kambayashi Ji, J; Liu, Y; Shakur, Y; Yoshitake, M, 2001) |
| "6 months, major adverse cardiac and cerebrovascular events (MACCE) occurred in 43 patients (17." | 1.39 | Long-term effectiveness and safety of triple versus dual antiplatelet therapy after percutaneous coronary intervention for unprotected left main coronary artery disease. ( Choi, RK; Hwang, HK; Lee, HJ; Li, H; Park, JS; Ro, YM; Yu, CW, 2013) |
| "Cilostazol, which was administered to prevent subacute stent thrombosis after percutaneous coronary intervention, might have contributed to the transient intraventricular obstruction." | 1.34 | Dynamic intraventricular obstruction in acute myocardial infarction with administration of cilostazol. ( Hoyano, M; Maeda, C; Miida, T; Oda, H; Ozaki, K; Takahashi, K; Takayama, T; Tsuchida, K; Yanagawa, T, 2007) |
| "Cilostazol is an effective antiplatelet agent with minimum side effects after elective, bailout, or primary stent implantation." | 1.30 | Antiplatelet treatment with cilostazol after stent implantation. ( Kojima, S; Kuramochi, M; Matsumoto, Y; Sugi, T; Yano, M; Yoshitomi, Y, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.55) | 18.7374 |
| 1990's | 4 (18.18) | 18.2507 |
| 2000's | 11 (50.00) | 29.6817 |
| 2010's | 6 (27.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, HJ | 2 |
| Yu, CW | 1 |
| Hwang, HK | 1 |
| Choi, RK | 1 |
| Park, JS | 1 |
| Li, H | 1 |
| Ro, YM | 1 |
| Park, KW | 1 |
| Kang, SH | 1 |
| Park, JJ | 1 |
| Yang, HM | 1 |
| Kang, HJ | 1 |
| Koo, BK | 1 |
| Park, BE | 1 |
| Cha, KS | 1 |
| Rhew, JY | 1 |
| Jeon, HK | 1 |
| Shin, ES | 1 |
| Oh, JH | 1 |
| Jeong, MH | 3 |
| Kim, S | 1 |
| Hwang, KK | 1 |
| Yoon, JH | 2 |
| Lee, SY | 1 |
| Park, TH | 1 |
| Moon, KW | 1 |
| Kwon, HM | 1 |
| Chae, IH | 2 |
| Kim, HS | 2 |
| Chen, Y | 1 |
| Zhang, Y | 1 |
| Tang, Y | 1 |
| Huang, X | 1 |
| Xie, Y | 1 |
| Im, E | 1 |
| Lee, SH | 1 |
| Kim, JS | 1 |
| Choi, D | 1 |
| Jang, Y | 1 |
| Jang, SW | 1 |
| Kim, DB | 1 |
| Kwon, BJ | 1 |
| Shin, D | 1 |
| Her, SH | 1 |
| Park, CS | 1 |
| Park, HJ | 1 |
| Park, MW | 1 |
| Cho, EJ | 1 |
| Rho, TH | 1 |
| Kim, JH | 2 |
| Grove, EL | 1 |
| Kristensen, SD | 1 |
| Chen, KY | 1 |
| Rha, SW | 1 |
| Li, YJ | 1 |
| Poddar, KL | 1 |
| Jin, Z | 1 |
| Minami, Y | 1 |
| Wang, L | 1 |
| Kim, EJ | 1 |
| Park, CG | 1 |
| Seo, HS | 1 |
| Oh, DJ | 1 |
| Ahn, YK | 1 |
| Hong, TJ | 1 |
| Kim, YJ | 1 |
| Hur, SH | 1 |
| Seong, IW | 1 |
| Chae, JK | 1 |
| Cho, MC | 1 |
| Bae, JH | 1 |
| Choi, DH | 1 |
| Jang, YS | 1 |
| Kim, CJ | 1 |
| Chung, WS | 1 |
| Seung, KB | 1 |
| Park, SJ | 3 |
| Park, KH | 1 |
| Lee, MG | 1 |
| Ko, JS | 1 |
| Sim, DS | 1 |
| Yoon, NS | 1 |
| Yoon, HJ | 1 |
| Hong, YJ | 1 |
| Kim, KH | 1 |
| Park, HW | 1 |
| Ahn, Y | 1 |
| Cho, JG | 1 |
| Park, JC | 1 |
| Kang, JC | 1 |
| Jeong, YH | 1 |
| Park, Y | 1 |
| Muse, WC | 1 |
| Kwon, TJ | 1 |
| Koh, JS | 1 |
| Hwang, SJ | 1 |
| Kwak, CH | 1 |
| Hwang, JY | 1 |
| Hong, MK | 2 |
| Mintz, GS | 1 |
| Lee, CW | 2 |
| Kim, YH | 1 |
| Lee, SW | 1 |
| Song, JM | 1 |
| Han, KH | 1 |
| Kang, DH | 1 |
| Song, JK | 1 |
| Kim, JJ | 2 |
| Park, SW | 2 |
| Tsuchikane, E | 1 |
| Takeda, Y | 1 |
| Nasu, K | 1 |
| Awata, N | 1 |
| Kobayashi, T | 1 |
| Schleinitz, MD | 1 |
| Olkin, I | 1 |
| Heidenreich, PA | 1 |
| Holmes, DR | 1 |
| Patel, TN | 1 |
| Kreindel, M | 1 |
| Lincoff, AM | 1 |
| Ozaki, K | 1 |
| Maeda, C | 1 |
| Takayama, T | 1 |
| Hoyano, M | 1 |
| Yanagawa, T | 1 |
| Tsuchida, K | 1 |
| Takahashi, K | 1 |
| Miida, T | 1 |
| Oda, H | 1 |
| Saitoh, S | 1 |
| Saito, T | 1 |
| Otake, A | 1 |
| Owada, T | 1 |
| Mitsugi, M | 1 |
| Hashimoto, H | 1 |
| Maruyama, Y | 1 |
| Ochiai, M | 1 |
| Isshiki, T | 1 |
| Takeshita, S | 1 |
| Eto, K | 1 |
| Toyoizumi, H | 1 |
| Sato, T | 1 |
| Miyashita, H | 1 |
| Yoshitomi, Y | 1 |
| Kojima, S | 1 |
| Sugi, T | 1 |
| Yano, M | 1 |
| Matsumoto, Y | 1 |
| Kuramochi, M | 1 |
| Park, HK | 1 |
| El-Beyrouty, C | 1 |
| Spinler, SA | 1 |
| Liu, Y | 1 |
| Shakur, Y | 1 |
| Yoshitake, M | 1 |
| Kambayashi Ji, J | 1 |
| Murohara, Y | 1 |
| Takatsu, Y | 1 |
| Yui, Y | 1 |
| Kawai, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of the Efficacy and Safety of New Platform Everolimus-eluting Coronary Stent System (Promus Element) With Zotarolimus-eluting Coronary Stent System (Endeavor Resolute) and Triple Anti-platelet Therapy With Double-dose Clopidogrel Anti-platelet [NCT01267734] | Phase 4 | 3,750 participants (Anticipated) | Interventional | 2010-06-30 | Recruiting | ||
| Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214] | Phase 4 | 826 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Randomized, Prospective , Open Label, Phase 4 Trial of Efficacy and Safety of Adjunctive Cilostazol in Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention With Drug-eluting Stent[NCT01261832] | Phase 4 | 951 participants (Anticipated) | Interventional | 2011-07-31 | Active, not recruiting | ||
| Revascularization With Paclitaxel-coated Balloon Angioplasty Versus Drug-eluting Stenting in Acute Myocardial Infarction - a Randomized Controlled Trial.[NCT02219802] | 120 participants (Anticipated) | Interventional | 2014-08-31 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for cilostazol and Coronary Thrombosis
| Article | Year |
|---|---|
Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons.
Topics: Aspirin; Cilostazol; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Hemorrhage; Humans | 2014 |
Update on oral antiplatelet therapy: principles, problems and promises.
Topics: Adenosine; Administration, Oral; Cardiovascular Diseases; Cilostazol; Coronary Artery Disease; Coron | 2009 |
Cilostazol, clopidogrel or ticlopidine to prevent sub-acute stent thrombosis: a meta-analysis of randomized trials.
Topics: Anticoagulants; Aspirin; Cilostazol; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Hu | 2004 |
Cilostazol for prevention of thrombosis and restenosis after intracoronary stenting.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cilostazol; Coronary Disease; Coronary Restenosis; | 2001 |
Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adenosine; Angioplasty, Balloon, Coronary; Animals; Arterial Oc | 2001 |
3 trials available for cilostazol and Coronary Thrombosis
| Article | Year |
|---|---|
Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-plate
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, | 2013 |
Balloon angioplasty plus cilostazol administration versus primary stenting of small coronary artery disease: final results of COMPASS.
Topics: Aged; Angioplasty, Balloon; Blood Vessel Prosthesis Implantation; Cilostazol; Combined Modality Ther | 2004 |
Comparison of cilostazol versus ticlopidine therapy after stent implantation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Coronary Disease; Coronary Thrombo | 1999 |
14 other studies available for cilostazol and Coronary Thrombosis
| Article | Year |
|---|---|
Long-term effectiveness and safety of triple versus dual antiplatelet therapy after percutaneous coronary intervention for unprotected left main coronary artery disease.
Topics: Aged; Cerebrovascular Disorders; Cilostazol; Coronary Restenosis; Coronary Stenosis; Coronary Thromb | 2013 |
Drug-eluting stent thrombosis after cilostazol withdrawal in a patient previously treated with triple antiplatelet therapy.
Topics: Aged; Cilostazol; Coronary Thrombosis; Digestive System Surgical Procedures; Drug-Eluting Stents; Hu | 2009 |
Death caused by simultaneous subacute stent thrombosis of sirolimus-eluting stents in left anterior descending artery and left circumflex artery.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Occ | 2010 |
Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Combined Modality Therapy; C | 2009 |
What is the optimal duration of triple anti-platelet therapy in patients with acute myocardial infarction undergoing drug-eluting stent implantation?
Topics: Aspirin; Cilostazol; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Female; Follow-Up Studie | 2011 |
Pharmacodynamic effect of clopidogrel therapy and switching to cilostazol in patients with the CYP2C19 loss-of-function allele (ACCEL-SWITCH) study.
Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Asian People; Aspirin; Cilostazol; Cl | 2012 |
Incidence, mechanism, predictors, and long-term prognosis of late stent malapposition after bare-metal stent implantation.
Topics: Aged; Aspirin; Atherectomy, Coronary; Catheterization; Cilostazol; Combined Modality Therapy; Corona | 2004 |
Antiplatelet therapy after percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Thrombosis; Drug Resistan | 2006 |
Use of ticlopidine and cilostazol after intracoronary drug-eluting stent placement in a patient with previous clopidogrel-induced thrombotic thrombocytopenic purpura: a case report.
Topics: ADAM Proteins; ADAMTS1 Protein; Aged; Apoptosis; Aspirin; Autoantibodies; Cilostazol; Clopidogrel; C | 2006 |
Dynamic intraventricular obstruction in acute myocardial infarction with administration of cilostazol.
Topics: Acute Disease; Aged; Cilostazol; Coronary Angiography; Coronary Thrombosis; Echocardiography; Electr | 2007 |
Cilostazol, a novel cyclic AMP phosphodiesterase inhibitor, prevents reocclusion after coronary arterial thrombolysis with recombinant tissue-type plasminogen activator.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Cilostazol; Coronary Thrombosis; Coronary Vessels; Dog | 1993 |
Use of cilostazol, a novel antiplatelet agent, in a post-Palmaz-Schatz stenting regimen.
Topics: Adult; Aged; Cilostazol; Coronary Angiography; Coronary Thrombosis; Female; Humans; Male; Middle Age | 1997 |
Antiplatelet treatment with cilostazol after stent implantation.
Topics: Aged; Cilostazol; Coronary Disease; Coronary Thrombosis; Evaluation Studies as Topic; Female; Follow | 1998 |
[The mode of action and clinical applications of phosphodiesterase inhibitors as anti-platelet drugs].
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Cilostazol; Coronary Disease; Coronary Thrombosis; Cyclic AMP; | 1989 |